Objective To evaluate mifepristone as an adjunct to, or replacement for, osmotic dilators for cervical preparation in surgical abortion after 19 weeks of gestation.
Introduction
Abortion remains a common procedure and an important component of a woman's reproductive healthcare, with the majority of abortions occurring at <12 weeks of gestation. 1, 2 Although abortion remains safe, the risk for major abortion-related complications increases with gestational age. 3, 4 Cervical preparation prior to second trimester dilation and evacuation (D&E) has been shown to decrease the risk of uterine perforation and cervical laceration and is recommended by the Society of Family Planning. 4 Osmotic dilators or misoprostol, or a combination, are the most common methods for cervical preparation utilised in the USA. 4, 5 Osmotic dilators, Dilapan-S and Laminaria, are cervical dilators that expand to a maximum diameter over 4-6 and 18-24 hours, respectively, to soften and dilate https://clinicaltrials.gov/ct2/show/NCT01862991 the cervix prior to D&E. 6, 7 The use of osmotic dilators requires the woman to have an outpatient procedure in the day(s) prior to the day of the D&E. 4 Prior to D&E, misoprostol aids in cervical softening and decreases the force required for mechanical cervical dilation. 8 Studies of mifepristone for medical abortion in the second trimester, showing a 40-50% reduction in abortion times, 9 influenced research on cervical preparation for second trimester surgical abortion and increased the use of mifepristone for cervical preparation prior to D&E. [10] [11] [12] [13] [14] [15] Mifepristone as an adjunct to osmotic dilators decreases the number of osmotic dilators needed after 19 weeks. 10, 11 Although both mifepristone and misoprostol are acceptable alternatives to dilators at 14-16 weeks, 8, 12, 16, 17 misoprostol results in more side effects than mifepristone, including cramping, chills and nausea. 11, 17, 18 There are limited data on mifepristone plus misoprostol cervical preparation for D&E and it has not been previously studied after 18 weeks of gestation. One published abstract reported that, between 15 and 18 weeks, mifepristone plus misoprostol was an acceptable alternative to overnight osmotic dilators and resulted in less pain than osmotic dilators alone. 15 The use of medication alone for cervical preparation would provide an opportunity to significantly expedite the overall abortion process, reducing discomfort, opportunity costs, and procedure times by eliminating the additional procedure of insertion of osmotic dilators that typically occurs 1 or 2 days prior to D&E. 4, 8, 19 We hypothesised that women who receive mifepristone and misoprostol prior to D&E would have surgical times that were not clinically significantly longer (non-inferior) compared with women receiving osmotic dilators and misoprostol. We also sought to study the effect of mifepristone as an adjunct to osmotic dilators in addition to misoprostol.
Methods
This was a site-stratified, double-blinded randomised, controlled non-inferiority trial comparing three different methods of cervical preparation prior to D&E at [19] [20] [21] [22] [23] 6/7 weeks of gestation: (1) mifepristone plus misoprostol, (2) osmotic dilators with mifepristone plus misoprostol, and (3) osmotic dilators with placebo plus misoprostol. The study was performed at Stanford Hospital and Clinics and Santa Clara Valley Medical Center between November 2013 and November 2015.
Participants had to be 18 years and older, have a live singleton pregnancy between 19 and 23 6/7 weeks of gestation by last menstrual period (LMP) confirmed by ultrasound, be able to provide informed consent and comply with study protocol, and be fluent in English or Spanish. The only exclusion criteria were a known allergy to misoprostol or mifepristone and being eligible for an outpatient procedure. Patients presenting to the clinical sites who were found to be eligible according to these study criteria were identified by their abortion provider and invited to speak with study personnel about participation following counselling and consent for the abortion procedure. If a woman agreed to be approached by study personnel, the study was presented to her and she was invited to participate and sign an informed consent document.
After informed consent, participants were randomised to one of three treatment groups by block randomisation, using a computer-generated, site-stratified, gestational agestratified, variable block size randomisation sequence to ensure balance of treatment groups. To maintain partial blinding of the study investigators and participants (with regard to the medication received), a Stanford employee not on the study team prepared sealed and labelled opaque envelopes containing a card indicating the treatment group to which the participant was assigned along with a smaller envelope containing study medication (i.e. 200 mg mifepristone or placebo). Participant demographic information and medical and surgical history were collected by study personnel verbally and entered into a study electronic database housed on an electronic data capture tool upon enrollment.
The day prior to their scheduled procedure, participants randomised to receive osmotic dilators received between 3 and 5 Dilapan-S (4 mm), at the discretion of the provider, with a paracervical block of 10 ml 1% lidocaine and an orally administered, blinded, study medication (mifepristone 200 mg or placebo). Those randomised to receive mifepristone without dilators were given mifepristone 200 mg orally. All participants at >22 weeks of gestation received 1 mg of intra-amniotic or intra-fetal digoxin, transabdominally. Administration of feticide in patients over 22 weeks is standard care at the clinical sites; methodology of administration was dependent on provider preference.
On the day of the procedure, all participants received buccal misoprostol 400 lg preoperatively, 4 with timing determined by study arm: 90 minutes prior to procedure for those with osmotic dilators 10 and 2-3 hours for those without. 8 Cervical dilation was assessed after administration of misoprostol via bimanual exam by the surgeon; if cervical dilation was <1 cm, a second dose of 400 lg buccal misoprostol for 2-4 hours was permitted per provider discretion. All procedures were performed in an operating room using standard evacuation techniques under deep sedation or general anaesthesia, induced and managed by an anaesthesiologist; the technique, including medication type and use of intubation, was not standardised.
After administration of anaesthesia, bimanual exam was performed by the surgeon and cervical dilation, consistency, position, and effacement recorded. 20 A paracervical injection of 10 ml of 1% lidocaine with 4 units of vasopressin was administered. If cervical dilation was estimated to be <3 cm on bimanual exam, dilation was determined using Pratt dilators, serially increasing the dilator until resistance was met and the dilator one size below was recorded as pre-procedure dilation. If estimated at 3 cm or greater, no additional assessment was performed. D&E was then performed under ultrasound guidance by an attending physician or family planning fellow (trainees who have completed their residency in Obstetrics and Gynaecology and are receiving specialty training in second trimester abortion). Procedure time was calculated from speculum insertion to speculum removal. Extraction time was calculated as first instrument in the uterus to the completion of abortion. Estimated blood loss (EBL), in millilitres, was visually estimated by the surgeon and any complications were recorded.
Visual analogue scales (VAS) were used to assess participant's pain at osmotic dilator placement (baseline, speculum insertion, paracervical block, osmotic dilator insertion, speculum removal) and on the day of D&E (before and after misoprostol, and 30 minutes postoperatively). In addition to pain, VAS was used to assess acceptability and overall experience. Postoperative complications were collected during a follow-up visit 10-14 days postoperatively by study personnel. For participants who did not present for a follow-up visit, study personnel called participants by phone to collect information about complications.
Our primary outcome was operative procedure time. Clinical inferiority was defined a priori as a more than 7-minute difference in operative time between any of the three distinct cervical preparations. In previous studies, operative procedure times were normally distributed with a standard deviation of~5 minutes; 10, 21 we rationalised that up to a 7-minute difference in procedure time would be represent a clinically acceptable difference between groups given the elimination of the additional preoperative time and discomfort associated with osmotic dilator insertion. Fourteen participants per group were required to show equivalence within 7 minutes for the procedure with a one-sided alpha of 0.025 and power of 0.90. The total sample size was increased by 20% to account for potential protocol violation and drop out, resulting in an estimated 17 participants needed per group, and the total enrollment goal was doubled to allow stratification by gestational age (19) (20) (21) 6/7 and 22-23 6/7 weeks) to 102. Secondary outcomes included cervical dilation, complications, side effects and pain experienced by participants, and acceptability.
Study data were collected and managed using REDCap (Research Electronic Data Capture) tool 22 hosted by Stanford University. SPSS version 23 was used for data analysis. When comparing categorical data across the three groups, Pearson chi square or Fisher's exact test was used, where appropriate, and continuous data were compared using a one-way ANOVA. For non-parametric data, Kruskal-Wallis tests were utilised. When comparing categorical data between two groups, Pearson chi square tests or Fisher's tests were used, where appropriate, and continuous data were compared using Student's t-tests. Mann-Whitney U-tests were used for non-parametric data. Procedure times and VAS pain scores are displayed as medians, as these were non-normally distributed data.
Results
From November 2013 through November 2015, 175 women were assessed for eligibility. Of them, 118 were eligible for participation and were approached: 80 (68%) accepted randomisation, were provided informed consent and were randomised. Due to slower than anticipated enrollment and administrative delays, we closed study enrollment early once the sample size needed for nonstratified analysis had been reached (but prior to reaching sample size goal for gestational age stratified analysis). Seventy-five participants were included in analysis (Figure 1) .
Demographic characteristics between groups were similar; mean gestational age was 21 weeks (P = 0.69). There were more nulliparous participants in group 2, dilators/ mifepristone (n = 10), compared with group 1, mifepristone (n = 4) and group 3, dilators/placebo (n = 3), but this was not a statistically significant difference (P = 0.11) ( Table 1) .
The majority of participants in both of the dilator groups received four dilators (P = 0.62) and had a similar median time with misoprostol (P = 0.71) ( Table 1) . Median time with misoprostol in the mifepristone participants, group 1, was 165 minutes (100-279). Pre-procedure cervical dilation was ≥3 cm in 4% of the mifepristone (group 1), 52% of the dilator/mifepristone (group 2), and 57% of the dilator/placebo (group 3) (P < 0.01). Manual dilation was required in 89, 22, and 19% of participants, respectively (P < 0.01) ( Table 1) .
Participants who received mifepristone plus misoprostol without osmotic dilators had an initial median pre-operative cervical dilation of 0.5 cm (range 0-4). The study protocol required 2-3 hours of preoperative misoprostol with a median of 2.7 hours (range 1.6-3 hours) as compared with 90 minutes for groups with osmotic dilators. Although the study protocol allowed for a second dose of misoprostol if preoperative cervical assessment was felt to be inadequate, this was only used once by the study surgeons and resulted in a change in cervical exam from less than 1 cm to 1-2 cm dilation between the post-medication assessment for the first and second dose.
Median total procedure time (excluding n = 3 cases with perforations) was statistically significantly different between the three groups (P < 0.01) ( Table 2) . When analysed separately, median procedure times (minutes) between the two dilator groups did not differ (P = 0.76) ( Table 3) and there was no difference when stratified by gestational weeks. Median procedure times between mifepristone participants (group 1) and dilators/placebo participants (group 3) were statistically different (P = 0.01) for the entire cohort, and within participants in the lower gestational age strata, 19-21 6/7 weeks (P = 0.01), but was not significant within gestations >22 weeks (P = 0.11) ( Table 4) .
When excluding the time required for additional manual dilation, the median time from completion of cervical dilation to completion of uterine evacuation was not significantly different between the three groups (P = 0.10) ( Table 2) . Similar effects were seen in sensitivity analysis when looking at gestational age cohorts (Table 2) , and for all gestational ages between the osmotic dilator groups (P = 0.70) ( Table 3 ) and mifepristone and dilators/placebo groups (P = 0.13) ( Table 4) .
The predefined non-inferiority margin of 7 minutes was not met for mifepristone plus misoprostol compared with dilators plus misoprostol, with a difference in means for total procedure time of 6.8 minutes (95% confidence interval 1.8-11.7) favouring dilators. When excluding the time required for manual dilation and analysing extraction time alone, the difference in means was 2.6 (95% CI À0.75 to 5.9), suggesting a (not statistically significant) shorter extraction time favouring dilators.
Median VAS pain scores between the three groups did not differ at any time-point (Table 5) . Notably, the highest median pain reported for all time-points was with osmotic dilator insertion.
Both attending physicians and family planning fellows performed procedures in this study: with fellows, the less experienced surgeon, being the lead surgeon in 61% of cases (n = 48). Complications occurred in seven cases -six by fellows and one by an attending physician (P = 0.03). All lacerations that were sutured were included as complications, with the smallest laceration of 3 mm being repaired. Although there was no significant difference among groups for overall complications (P = 0.12), there were more cervical lacerations with mifepristone plus misoprostol (n = 5) than with dilators plus mifepristone (n = 0) and dilators plus placebo (n = 1) (P = 0.03). All but one cervical laceration in the mifepristone plus misoprostol group were low cervical lacerations and were easily repaired. Of the participants who had a laceration, two had also experienced a uterine perforation; both were in the mifepristone plus misoprostol group. There was no difference in uterine perforation across groups: group 1: n = 2, group 2: n = 1; group 3: n = 0 (P = 0.77). Using a binary logistic regression, no aspect of the preoperative cervical exam -cervical position, dilation, length nor consistency -was predictive of complications. Reported EBL did not differ between groups (P = 0.51). 14 (52) 12 (44) 10 (48) 0.96*** Prior caesarean section, n (%)
4 (15) 1 (4) 3 (14) 0.41*** Prior cervical procedure, n (%)
3 (11) 1 (4) 0 (0) 
Discussion

Main findings
When comparing all three cervical preparations, there was a significant difference in the median total procedure time, but when eliminating the time required for dilation, there was no significant difference in median time from completion of dilation to completion of evacuation. The addition of mifepristone, when comparing participants who received osmotic dilators, did not appear to shorten procedure times in our protocol that included pre-procedure misoprostol for any group. Preoperative pain was greater for those who received osmotic dilators and pain with their insertion exceeded pain associated with preoperative misoprostol. An increased risk of cervical laceration was seen in the mifepristone group but only when procedures were performed by a less experienced, trainee level, surgeon.
Strengths and limitations
This study is among the first to explore the use of mifepristone and misoprostol for cervical preparation for surgical abortion after 19 weeks of gestation in lieu of osmotic dilators. Strengths of our study include the design as a randomised trial with double-blinding in the two arms that received osmotic dilators, but blinding was necessarily limited in the arm not receiving osmotic dilators. We chose Table 4 . Procedure times among subjects randomised to receive osmotic dilators alone and mifepristone alone, median minutes (range)
Mifepristone plus misoprostol
Osmotic dilators with placebo plus misoprostol not to include a sham dilator placement, as part of the effect of eliminating the time required for dilators on the overall experience would not be appreciated by participants. Another strength is that this was a multi-site study that included multiple providers and trainees, increasing its external validity. Our study is limited in that we were unable to reach our intended sample size and therefore lacked statistical power to stratify by gestational age group, limiting interpretation of analysis stratified by gestational age.
P-value
Interpretation
Procedure times were more than 6 minutes longer with mifepristone and misoprostol, and (when accounting for 95% confidence interval) did not meet the non-inferiority margin of 7 minutes. However, by eliminating the insertion of osmotic dilators, participants did not require a preoperative procedure clinic visit, thus decreasing both provider and patient time spent and, importantly, patient discomfort. Additionally, replacing osmotic dilators with medications has the potential to increase access to second trimester services by eliminating the need for an experienced provider to place the dilators the day prior to the procedure. Using medications alone for cervical preparation could allow mifepristone to be administered by a remote referring provider prior to referral to a second trimester provider. This has the potential to decrease the number of days away, when women must travel to obtain a second trimester procedure.
When osmotic dilators and misoprostol are used for cervical preparation, the addition of mifepristone does not seem to shorten procedure times (mean and median difference in procedure time was 1 minute). Previous larger studies showed more benefit with mifepristone as an adjunct to osmotic dilators in gestations >19 weeks and in nulliparous patients. 11 The cost of mifepristone in some settings may be a barrier to its use and additional studies are needed to support routine use of mifepristone as an adjunct to osmotic dilators.
We demonstrate that using both misoprostol and mifepristone as an adjunct to synthetic osmotic dilators, fewer osmotic dilators achieved a similar cervical dilation compared with dilation reported in previous studies in this gestational age group. 11, 18 Thus, this use of medication adjuncts has the potential to decrease the pain and cost associated with osmotic dilator insertion and is consistent with previous work that focused on reducing from two sets of dilators to one. 10 The insertion of fewer osmotic dilators offsets the additional cost of mifepristone without increasing side effects or pain, as mifepristone alone did not increase pre-procedure pain.
Although increases in side effects including pain, chills, and fever with misoprostol have been reported in recent studies, 11, 18 we found the pain associated with administration of misoprostol in our study to be less than that associated with osmotic dilator insertion. Furthermore, if the pain associated with insertion of dilators continued overnight, for the duration of time the osmotic dilators are in place, the total pain experienced by patients would be significantly greater than pain associated with misoprostol. In addition, our study found the addition of mifepristone did not increase reported pain after administration of misoprostol when compared with placebo.
We observed more complications in participants where trainees (fellows) were the primary surgeon. One series of second trimester abortion by four experienced providers reported cervical laceration in 3%, 23 and a recent study including trainees (residents and fellows) reported a 9.7% incidence of cervical laceration that required suturing. 18 The Society of Family Planning recommends that in cervical preparation for second trimester D&E, forgoing osmotic dilators may be considered but should be limited to experienced providers. 8 The use of mifepristone and misoprostol softens the cervix, decreasing the force required for manual cervical dilation, 8 but it may also make the cervix more prone to cervical laceration. 18 Therefore, manual cervical dilation is an important skill if adopting protocols that eliminate osmotic dilation to manage inadequate cervical dilation safely. 24 We found that mifepristone plus misoprostol, without osmotic dilators, resulted in less apparent preoperative cervical dilation and an increased rate of cervical laceration (19%) . Applying what is known from medication (induction) abortion literature -that gestations >19 weeks frequently require multiple doses of misoprostol after mifepristone administration 25 -an additional dose of misoprostol may be beneficial in future protocols. The use of multiple doses of misoprostol, with the use of serial osmotic dilators, prior to assisted delivery or surgical evacuation of the fetus in the second trimester has been described previously. 26 Future studies looking at pharmacologic options for eliminating osmotic dilators for cervical preparation should study the effect of multiple doses. However, multiple dosing of misoprostol in a setting where a woman can be monitored for signs of immediate expulsion and treated for any medication-related side effects, including pain, may be a limitation to using protocols that eliminate osmotic dilators in some abortion care settings.
Conclusion
Use of mifepristone plus misoprostol -without osmotic dilators -results in longer procedure times but removed the most painful aspect of the abortion process. Provider experience may impact risk when eliminating dilators. Where feasible, elimination of osmotic dilators decreases patient pain and offers potential to reduce the burden and opportunity cost of cervical preparation.
When using misoprostol with osmotic dilators, the addition of mifepristone did not result in a clinically significant difference in procedure time; however, it also did not increase side effects associated with preoperative misoprostol. Use of adjuncts may decrease the number of osmotic dilators needed, but the cost of mifepristone should be considered if implementing its routine use as an adjunct to misoprostol and osmotic dilators.
Larger studies are needed to explore further the safety, feasibility, and optimal protocol for reduction or omission of osmotic dilators after 19 weeks of gestation.
